The United States Monoclonal Antibodies Industry is Expected to Reach $45.2 Billion by 2027 – ResearchAndMarkets.com

The United States Monoclonal Antibodies Industry is Expected to Reach $45.2 Billion by 2027 – ResearchAndMarkets.com




The United States Monoclonal Antibodies Industry is Expected to Reach $45.2 Billion by 2027 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Monoclonal Antibodies Market Research Report by Source Type (Chimeric, Human, and Humanized), Production Type, Indication, End-User, State – United States Forecast to 2027 – Cumulative Impact of COVID-19” report has been added to ResearchAndMarkets.com’s offering.

The United States Monoclonal Antibodies Market size was estimated at USD 20.40 billion in 2021, USD 24.06 billion in 2022, and is projected to grow at a Compound Annual Growth Rate (CAGR) of 14.21% to reach USD 45.29 billion by 2027.

Companies Mentioned

  • Abbott Laboratories
  • AbbVie, Inc
  • AbGenomics
  • ADC Therapeutics
  • ALMAC Group
  • Amgen Inc.
  • Astellas Pharma Inc
  • AstraZeneca PLC
  • Bayer AG
  • Biogen Idec Inc.
  • Bristol Myers Squibb
  • Daiichi Sankyo Company, Limited
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • GenScript Biotech Corporation
  • GlaxoSmithKline PLC
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Mylan N.V.
  • Novartis International AG
  • Novo Nordisk A/S
  • Pfizer Inc
  • Sanofi S.A.
  • Seagen Inc.
  • Shanghai Junshi Biosciences Co., Ltd.
  • Thermo Fisher Scientific, Inc

Competitive Strategic Window:

The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes the vendors in the Monoclonal Antibodies Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:

The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players

5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the United States Monoclonal Antibodies Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the United States Monoclonal Antibodies Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the United States Monoclonal Antibodies Market?

4. What is the competitive strategic window for opportunities in the United States Monoclonal Antibodies Market?

5. What are the technology trends and regulatory frameworks in the United States Monoclonal Antibodies Market?

6. What is the market share of the leading vendors in the United States Monoclonal Antibodies Market?

7. What modes and strategic moves are considered suitable for entering the United States Monoclonal Antibodies Market?

Key Topics Covered:

1. Preface

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

5.1. Market Dynamics

5.1.1. Drivers

5.1.2. Restraints

5.1.3. Opportunities

5.1.4. Challenges

5.2. Cumulative Impact of COVID-19

6. Monoclonal Antibodies Market, by Source Type

6.1. Introduction

6.2. Chimeric

6.3. Human

6.4. Humanized

6.5. Murine

7. Monoclonal Antibodies Market, by Production Type

7.1. Introduction

7.2. In Vitro

7.3. In Vivo

8. Monoclonal Antibodies Market, by Indication

8.1. Introduction

8.2. Autoimmune Diseases

8.3. Cancer

8.4. Infectious Diseases

8.5. Inflammatory Diseases

8.6. Microbial Diseases

9. Monoclonal Antibodies Market, by End-User

9.1. Introduction

9.2. Hospitals

9.3. Research Institutes

10. California Monoclonal Antibodies Market

11. Florida Monoclonal Antibodies Market

12. Illinois Monoclonal Antibodies Market

13. New York Monoclonal Antibodies Market

14. Ohio Monoclonal Antibodies Market

15. Pennsylvania Monoclonal Antibodies Market

16. Texas Monoclonal Antibodies Market

17. Competitive Landscape

17.1. FPNV Positioning Matrix

17.1.1. Quadrants

17.1.2. Business Strategy

17.1.3. Product Satisfaction

17.2. Market Ranking Analysis

17.3. Market Share Analysis, By Key Player

17.4. Competitive Scenario

17.4.1. Merger & Acquisition

17.4.2. Agreement, Collaboration, & Partnership

17.4.3. New Product Launch & Enhancement

17.4.4. Investment & Funding

17.4.5. Award, Recognition, & Expansion

18. Company Usability Profiles

19. Appendix

For more information about this report visit https://www.researchandmarkets.com/r/8p0vx0

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900